PSD-95 (Postsynaptic Density Protein 95)

Migration, Crosslink

📖

PSD-95 (Postsynaptic Density Protein 95)

active

wiki page Created: 2026-04-02T07:20:06 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-entities-psd-95

📖 Wiki Page

entity1511 wordssynced 2026-04-02

Introduction

Psd 95 (Postsynaptic Density Protein 95) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

...

Introduction

Psd 95 (Postsynaptic Density Protein 95) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

Mermaid diagram (expand to render)

PSD-95 (also known as SAP-90 or DLG4, Discs Large Homolog 4) is the most abundant scaffolding protein in the excitatory postsynaptic density (PSD), a dense protein complex located at the postsynaptic membrane of glutamatergic synapses. Encoded by the DLG4 gene on chromosome 17p13.1, PSD-95 organizes the molecular machinery required for synaptic signaling, plasticity, and structural stability by clustering NMDA receptor receptors], AMPA receptors, adhesion molecules, signaling enzymes, and cytoskeletal elements into a supramolecular signaling complex at dendritic spines.[@sheng2002] [@gylys2004]

In neurodegenerative diseases, PSD-95 dysfunction and loss are intimately linked to synaptic dysfunction — the earliest detectable functional abnormality in Alzheimer's disease, Huntington's disease, and other neurodegenerative conditions. Because synaptic loss is the strongest pathological correlate of cognitive decline in AD (more so than plaques or tangles), understanding PSD-95 regulation is critical for developing therapies that preserve synaptic function in neurodegeneration.[@gylys2004] [@chen2011]

Structure and Domains

PSD-95 is a 724-amino acid member of the membrane-associated guanylate kinase (MAGUK) protein family with a characteristic multi-domain architecture: [@macgillavry2013]

Domain Organization

PDZ domains 1, 2, and 3: Protein-protein interaction modules that bind the C-terminal tails of transmembrane proteins. PDZ1 and PDZ2 are essential for:

Clustering NMDA receptor receptors] (binding GluN2A and GluN2B subunits)
Anchoring stargazin/TARPs, which in turn tether AMPA receptors
Interacting with neuroligins at the synaptic cleft

2. SH3 domain: Binds proline-rich sequences in signaling molecules (e.g., SynGAP, GKAP/SAPAP)

Guanylate kinase (GK) domain: A catalytically inactive pseudokinase that functions as a protein interaction module, binding GKAP/SAPAP and other PSD scaffolding proteins

Palmitoylation sites (Cys3 and Cys5): N-terminal dual palmitoylation anchors PSD-95 to the postsynaptic membrane; dynamic palmitoylation/depalmitoylation regulates synaptic targeting and turnover[@chen2011]

PSD Architecture

PSD-95 is the central organizing hub of the PSD, estimated at ~300–400 copies per synapse. Through its multi-domain interactions, it creates a layered molecular architecture: [@elias2006]

Layer 1 (membrane-proximal): PSD-95 anchors receptors and adhesion molecules
Layer 2: Intermediate scaffolds (GKAP/SAPAP, Shank proteins)
Layer 3 (cytoplasmic): Shank proteins connect to the actin cytoskeleton via Homer and cortactin

This architecture ensures that signal transduction machinery is precisely positioned beneath glutamate receptors for efficient synaptic transmission and plasticity.[@macgillavry2013] [@meyer2014]

Functions in the Nervous System

Synaptic Receptor Clustering and Stabilization

PSD-95 is the primary scaffold for clustering glutamate receptors at excitatory synapses: [@bhatt2022]

NMDA receptor] receptors: PSD-95 binds NMDA receptor receptor] GluN2 subunits, anchoring them at the synapse and coupling them to downstream signaling pathways (nNOS, SynGAP, Ras/ERK)
AMPA receptors: PSD-95 indirectly clusters AMPA receptors via stargazin/TARP auxiliary subunits, regulating synaptic AMPA receptor content — the primary determinant of synaptic strength
Receptor density: PSD-95 content sets the maximum receptor capacity at each synapse, directly controlling synaptic efficacy[@elias2006]

Synaptic Plasticity

PSD-95 is essential for long-term potentiation (LTP and long-term depression (LTD) — the molecular mechanisms underlying learning and memory: [@bhatt2020]

LTP: Insertion of additional AMPA receptors into PSD-95 scaffolds strengthens the synapse
LTD: Removal of AMPA receptors from PSD-95 slots weakens the synapse
Structural plasticity: PSD-95 content correlates with dendritic spine size, linking molecular organization to synaptic morphology
CaMKII phosphorylation of PSD-95 stabilizes the protein at synapses during LTP[@meyer2014]

Neuroprotective vs. Excitotoxic Signaling

PSD-95 positions nNOS (neuronal nitric oxide synthase) adjacent to NMDA receptor receptors], coupling NMDA receptor](/proteins/nmda-receptor) receptor activation to nitric oxide production. This PSD-95/nNOS/NMDA receptor complex has a dual role: [@nilsson2022]

Physiological: Supports synaptic signaling and plasticity at normal activation levels
Pathological: During excitotoxicity (excessive glutamate stimulation), the PSD-95/nNOS complex generates toxic levels of NO, leading to peroxynitrite formation, DNA damage, and neuronal death

This has led to the development of PSD-95/nNOS interaction inhibitors as potential neuroprotective agents (see Therapeutic Targeting below).[@bhatt2022] [@aguilarvalles2025]

Role in Neurodegenerative Diseases

Alzheimer's Disease

PSD-95 loss is a central feature of [synaptic dysfunction in AD]: [@nash2019]

Pathological changes: [@bhatt2008]

PSD-95 protein levels are reduced by 25–50% in the hippocampus and cortex of AD patients
The temporal pattern is complex: early compensatory upregulation (possibly protective) precedes progressive loss as disease advances
PSD-95 loss correlates strongly with cognitive decline on Mini-Mental State Examination (MMSE) scores
Amyloid-Beta oligomers directly reduce PSD-95 at synapses through multiple mechanisms[@gylys2004]

Mechanisms of PSD-95 loss in AD:

Aβ oligomer-induced internalization: Soluble Aβ oligomers bind to synaptic sites and trigger PSD-95 removal from spines via caspase-3 cleavage and ubiquitin-proteasome degradation

Tau(/proteins/tau)-mediated toxicity: Hyperphosphorylated tau] targets Fyn kinase to dendritic spines, where it phosphorylates NMDA receptor receptor] GluN2B subunits, destabilizing the PSD-95/NMDA receptor complex

Depalmitoylation: Increased activity of palmitoyl thioesterases (APT1/APT2) depalmitoylates PSD-95, releasing it from the postsynaptic membrane

Transcriptional repression: DLG4 gene expression is downregulated in AD brain[@bhatt2020]

Biomarker potential:
CSF levels of PSD-95 are elevated in AD patients (reflecting synaptic release from degenerating synapses), and PSD-95 is being evaluated as a synaptic biomarker alongside other synaptic proteins (neurogranin, SNAP-25, synaptotagmin-1).[@nilsson2022]

Huntington's Disease

In Huntington's disease, PSD-95 plays a critical role in the selective vulnerability of medium spiny neurons in the striatum:

Mutant huntingtin disrupts PSD-95 palmitoylation by binding and inhibiting HIP14 (huntingtin-interacting protein 14), a palmitoyl transferase
Loss of PSD-95 palmitoylation leads to synaptic destabilization and increased vulnerability to excitotoxicity
PSD-95 overexpression sensitizes striatal neurons to NMDA receptor-mediated excitotoxicity by enhancing the PSD-95/nNOS/NMDA receptor complex
Restoring Dlg4 expression via artificial transcription factors ameliorates cognitive and motor deficits in HD mouse models[@aguilarvalles2025]

Parkinson's Disease

In Parkinson's disease, PSD-95 changes are observed at corticostriatal synapses following [dopaminergic denervation]:

Loss of dopaminergic input to the striatum alters glutamatergic signaling at medium spiny neuron spines
PSD-95 redistribution at corticostriatal synapses contributes to the altered excitability that underlies motor symptoms
L-DOPA-induced dyskinesias are associated with abnormal PSD-95 accumulation at synapses[@nash2019]

Prion Diseases

In prion disease, PSD-95 loss from hippocampal synapses occurs early and correlates with the onset of cognitive symptoms, preceding neuronal loss. Misfolded prion protein (PrPSc) disrupts PSD-95 trafficking and clustering.[@bhatt2008]

Therapeutic Targeting

PSD-95/nNOS Disruption (Neuroprotection)

Disrupting the PSD-95/nNOS interaction selectively blocks excitotoxic NO production without impairing normal NMDA receptor signaling:

NA-1 (Nerinetide/Tat-NR2B9c): A peptide that disrupts PSD-95/NMDA receptor interaction; advanced to Phase III clinical trials for acute ischemic stroke. The ESCAPE-NA1 trial showed neuroprotection in stroke patients not treated with tPA-based thrombolytics
This approach has potential for neurodegenerative diseases where excitotoxicity contributes to neuronal death[@bhatt2022]

Palmitoylation Stabilization

Inhibiting depalmitoylation (blocking APT1/APT2) increases synaptic PSD-95 levels and protects synapses from Aβ-induced destabilization:

ML349 (APT2 inhibitor) increases PSD-95 clustering and protects synapses in AD models
This approach targets the mechanism of synaptic loss rather than the upstream amyloid or tau pathology[@bhatt2020]

Synaptic Restoration Strategies

PSD-95 gene upregulation: Artificial transcription factors targeting the DLG4 promoter can restore PSD-95 expression in disease models
BDNF and neurotrophic support: BDNF signaling enhances PSD-95 expression and synaptic maintenance
Exercise: Physical activity increases PSD-95 levels in the hippocampus, contributing to exercise-induced neuroprotection

Brain Atlas Resources

Allen Human Brain Atlas: [PSD-95 expression search](https://human.brain-map.org/microarray/search/show?search_term=PSD-95)
Allen Mouse Brain Atlas: [PSD-95 search](https://mouse.brain-map.org/search/index.html?query=PSD-95)
Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
BrainSpan Developmental Transcriptome: [PSD-95 developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=PSD-95)
[Medium Spiny Neurons (MSNs)](/cell-types/neurons)
[Amyloid-Beta (Aβ))))))](/proteins/amyloid-beta)
[Brain-Derived Neurotrophic Factor (BDNF)](/proteins/bdnf)
[Huntingtin (HTT))))))](/genes/htt)
[tau protein](/proteins/tau)](/proteins/tau)

External Links

[UniProt — DLG4 Human](https://www.uniprot.org/uniprot/P78352)
[OMIM — DLG4](https://www.omim.org/entry/602887)
[NCBI Gene — DLG4](https://www.ncbi.nlm.nih.gov/gene/1742)
[Allen Brain Atlas — DLG4 Expression](https://human.brain-map.org/microarray/search/show?search_term=DLG4)

Background

The study of Psd 95 (Postsynaptic Density Protein 95) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

[Unknown, Sheng & Kim, Postsynaptic Signaling and Plasticity Mechanisms, Science 2002 (2002)](https://doi.org/10.1126/science.1075333)

[Gylys et al., Synaptic Changes in Alzheimer's Disease: Increased Amyloid-β and Gliosis, Am J Pathol 2004 (2004)](https://doi.org/10.1016/S0002-9440(10)

[Chen et al., PSD-95 Is Required to Sustain the Molecular Organization of the Postsynaptic Density, J Neurosci 2011 (2011)](https://doi.org/10.1523/JNEUROSCI.5968-10.2011)

[MacGillavry et al., Nanoscale Scaffolding Domains within the Postsynaptic Density, Nature Neuroscience 2013 (2013)](https://doi.org/10.1038/nn.3546)

[Elias et al., Synapse-Specific and Developmentally Regulated Targeting of AMPA Receptors by a Family of MAGUK Scaffolding Proteins, Neuron 2006 (2006)](https://doi.org/10.1016/j.neuron.2006.09.012)

[Meyer et al., Balance and Stability of Synaptic Structures During Synaptic Plasticity, Neuron 2014 (2014)](https://doi.org/10.1016/j.neuron.2014.02.031)

[Bhatt et al., Clinical PSD-95 Inhibitors for Neuroprotection, Expert Opinion on Investigational Drugs 2022 (2022)](https://doi.org/10.1080/13543784.2022.2044784)

[Bhatt et al., Inhibition of Depalmitoylation Stabilizes PSD-95 Against Amyloid-β Toxicity, J Neurosci 2020 (2020)](https://doi.org/10.1523/JNEUROSCI.0986-19.2020)

[Nilsson et al., Increased Levels of PSD-95, SNAP-25, and Neurogranin in CSF of AD Patients, Alzheimers Research & Therapy 2022 (2022)](https://doi.org/10.1186/s13195-022-01002-x)

[Aguilar-Valles et al., Restoring Endogenous Dlg4/PSD95 Expression Ameliorates Deficits in R6/2 HD Mice, Clinical Epigenetics 2025 (2025)](https://doi.org/10.1186/s13148-025-01903-2)

[Nash et al., DJ-1 Deficiency Alters Striatal Signaling via PSD-95 Changes, Neurobiology of Disease 2019 (2019)](https://doi.org/10.1016/j.nbd.2019.05.006)

[Bhatt et al., PSD-95 Expression in Alzheimer's Disease and Neurodegeneration, Neurobiology of Aging 2008 (2008)](https://doi.org/10.1016/j.neurobiolaging.2007.04.010)

Pathway Diagram

The following diagram shows the key molecular relationships involving PSD-95 (Postsynaptic Density Protein 95) discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

entities-psd-95

▸Metadataorigin_type: v1_polymorphic_backfill

slug	entities-psd-95
kg_node_id	None
entity_type	entity
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-7d782946d7d8
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'entities-psd-95'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

100%

Debates

0

Incoming

80

Outgoing

117

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

PSD-95 (Postsynaptic Density Protein 95)

Introduction

Overview

Introduction

Overview

Structure and Domains

Domain Organization

PSD Architecture

Functions in the Nervous System

Synaptic Receptor Clustering and Stabilization

Synaptic Plasticity

Neuroprotective vs. Excitotoxic Signaling

Role in Neurodegenerative Diseases

Alzheimer's Disease

Huntington's Disease

Parkinson's Disease

Prion Diseases

Therapeutic Targeting

PSD-95/nNOS Disruption (Neuroprotection)

Palmitoylation Stabilization

Synaptic Restoration Strategies

Brain Atlas Resources

External Links

Background

References

Pathway Diagram

💬 Discussion